GLP‑1 maker inspection warning
- The FDA issued a warning letter after inspectors were refused access to a facility producing semaglutide and tirzepatide. - The warning specifically involved a manufacturer tied to widely used GLP‑1 products. - That quality concern arrives as prescribing rises and a new real‑world study links GLP‑1s to mild erectile dysfunction risk ( ).
The Food and Drug Administration warned New Life Pharma after inspectors were blocked from parts of a New Jersey facility making semaglutide and tirzepatide injections. (biospace.com) FDA inspectors visited the plant in February 2026 and found New Life was producing sterile multi-dose vials of semaglutide and tirzepatide, the active ingredients used in Ozempic, Wegovy, Mounjaro and Zepbound. The agency said the company denied access to two areas of the production suite. (biospace.com) Under federal law, a drug can be deemed adulterated if a manufacturer delays, denies, limits or refuses an inspection. FDA’s guidance says that standard applies when a company blocks entry to parts of a facility where drugs are made, packed or held. (fda.gov) GLP-1 drugs mimic a gut hormone that helps control blood sugar and appetite. Semaglutide and tirzepatide became household names as demand surged for diabetes treatment and weight loss, pulling compounders and telehealth sellers deeper into the market. (thelancet.com, fda.gov) That demand showed up in prescribing data from 2018 to 2023. An American Journal of Managed Care study found GLP-1 prescribing rose significantly over that period, and semaglutide approved for weight loss reached a 60% share in the nondiabetic overweight or obese group. (ajmc.com) The warning also lands after FDA tightened its stance on compounded GLP-1 copies as branded supply stabilized. FDA said in 2025 that its enforcement grace periods tied to semaglutide and tirzepatide shortages had ended or were ending, while stressing it could still act against products that appear substandard or unsafe. (fda.gov) FDA has separately told patients that compounded GLP-1 drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before marketing. The agency also said some compounded injectable GLP-1 products arrived warm or with inadequate ice packs, which can affect quality. (fda.gov) At the same time, researchers are still mapping the drugs’ side effects outside clinical trials. A new real-world study of men with type 2 diabetes using electronic health records from January 2019 to September 2024 found 35.2 erectile dysfunction cases per 1,000 person-years among GLP-1 users versus 28.0 among DPP-4 inhibitor users, with an initial hazard ratio of 1.26. (medicaldialogues.in) That study did not show causation. After extra calibration for residual bias, the association was no longer statistically significant, and the authors said randomized trials are still needed. (medicaldialogues.in) For patients, the immediate issue is simpler than the science: FDA says it must be able to inspect drug plants, especially when they are making sterile injections used by millions of Americans. (fda.gov, biospace.com)
